Anna Potash, MD
Psychiatry · Mineola, NYNPI 1598760019
Payments from drug & device makers
Across 380 payments — averaging $29.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- AbbVie$851
- Neurocrine Biosciences, Inc.$833
- Axsome Therapeutics, Inc.$773
- plus $3K from 16 others
What the payments were for
- Food & beverage$11,17099%
- Education$1011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 91 | $3,075 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $1,253 |
| Alkermes, Inc. | 31 | $1,057 |
| AbbVie(2 entities) | 32 | $851 |
| Neurocrine Biosciences, Inc. | 20 | $833 |
| Axsome Therapeutics, Inc. | 17 | $773 |
| Lundbeck LLC | 25 | $504 |
| E.r. Squibb & Sons, L.L.C. | 8 | $360 |
| Avanir Pharmaceuticals, Inc. | 15 | $342 |
| Sunovion Pharmaceuticals Inc. | 14 | $329 |
| Almatica Pharma LLC | 15 | $297 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $273 |
| Teva Pharmaceuticals USA, Inc. | 9 | $254 |
| Johnson & Johnson | 4 | $252 |
| Bausch Health US, LLC | 12 | $220 |
| Merck | 11 | $201 |
| Nestle Healthcare Nutrition Inc. | 4 | $90 |
| Shire North American Group Inc | 3 | $75 |
| Neos Therapeutics, LP | 4 | $70 |
| Eisai Inc. | 3 | $68 |
| Vanda Pharmaceuticals Inc. | 2 | $54 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,480
- REXULTI$754
- Auvelity$374
- INGREZZA$324
- ABILIFY MAINTENA$242
- CAPLYTA$137
- COBENFY$135
- SPRAVATO$125
- VRAYLAR$125
- ABILIFY ASIMTUFII$121
How this compares
$11,271 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 429 | $605,920 |
| TrintellixVortioxetine Hydrobromide | 524 | $250,311 |
| NuedextaDextromethorphan Hbr/Quinidine | 122 | $178,263 |
| ZenpepLipase/Protease/Amylase | 82 | $116,917 |
| CaplytaLumateperone Tosylate | 65 | $103,135 |
| BelsomraSuvorexant | 216 | $91,326 |
| AplenzinBupropion Hbr | 38 | $91,156 |
| VraylarCariprazine Hcl | 49 | $70,264 |
| NamzaricMemantine Hcl/Donepezil Hcl | 94 | $54,736 |
| CreonLipase/Protease/Amylase | 31 | $42,130 |
| Wellbutrin XlBupropion Hcl | 12 | $30,801 |
| Loreev XrLorazepam | 64 | $27,422 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $18,412 |
| LatudaLurasidone Hcl | 14 | $18,075 |
| Memantine Hcl ErMemantine Hcl | 305 | $17,872 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $3,075 | $605,920429 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $273 | $250,311524 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $342 | $178,263122 claims |
| AbbVieVraylar, Namzaric, Creon | $851 | $167,131174 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,253 | $103,13565 claims |
| MerckBelsomra | $201 | $91,326216 claims |
| Bausch Health US, LLCAplenzin | $220 | $91,15638 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $297 | $28,762249 claims |
| Alkermes, Inc.Lybalvi | $1,057 | $18,41213 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $329 | $18,07514 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $42 | $6,33814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Mineola
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
- Paul EderNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.